VetDC Announces New TANOVEA®-CA1 Publication and State of the Art Presentation at the Veterinary Cancer Society 2017 Annual Conference

,

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

Read more…